Needham

Candel Therapeutics Appoints Mace L. Rothenberg, MD, as Senior Advisor to the Chief Executive Officer

Tuesday, October 19, 2021 - 1:00pm

I am delighted to welcomeMaceas an advisor to Candel Therapeuticsto further strengthen ourteam, said Dr.Tak.

Key Points: 
  • I am delighted to welcomeMaceas an advisor to Candel Therapeuticsto further strengthen ourteam, said Dr.Tak.
  • Prior to joining Candel, Dr. Rothenberg served as Chief Medical Officer of Pfizer.
  • He also served as an Associate Professor of Medicine at the University of Texas Health Science Center at San Antonio and Executive Officer of the Southwest Oncology Group.
  • Candel is at the forefront of one of the most exciting approaches in cancer immunotherapy, said Dr. Rothenberg.

Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering

Monday, October 18, 2021 - 10:45pm

NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced the closing on October 18, 2021 of its initial public offering (the Offering) of 5,000,000 shares of common stock at a price to the public of $14.00 per share for total gross proceeds of $70,000,000 before deducting underwriting discounts and commissions and estimated offering expenses.

Key Points: 
  • NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced the closing on October 18, 2021 of its initial public offering (the Offering) of 5,000,000 shares of common stock at a price to the public of $14.00 per share for total gross proceeds of $70,000,000 before deducting underwriting discounts and commissions and estimated offering expenses.
  • In addition, Lucid has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from Lucid at the initial public offering price less underwriting discounts and commissions.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).
  • Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing.

Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering

Monday, October 18, 2021 - 11:09pm

Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced the closing on October 18, 2021 of its initial public offering (the Offering) of 5,000,000 shares of common stock at a price to the public of $14.00 per share for total gross proceeds of $70,000,000 before deducting underwriting discounts and commissions and estimated offering expenses.

Key Points: 
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced the closing on October 18, 2021 of its initial public offering (the Offering) of 5,000,000 shares of common stock at a price to the public of $14.00 per share for total gross proceeds of $70,000,000 before deducting underwriting discounts and commissions and estimated offering expenses.
  • In addition, Lucid has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from Lucid at the initial public offering price less underwriting discounts and commissions.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).
  • Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing.

Paragon 28, Inc. Announces Pricing of Initial Public Offering

Friday, October 15, 2021 - 10:52pm

ENGLEWOOD, Colo., Oct. 15, 2021 /PRNewswire/ --Paragon 28, Inc. (NYSE: FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Key Points: 
  • ENGLEWOOD, Colo., Oct. 15, 2021 /PRNewswire/ --Paragon 28, Inc. (NYSE: FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.
  • PARAGON's common stock is expected to begin trading on the New York Stock Exchange on October 15, 2021, under the ticker symbol "FNA."
  • The offering is expected to close on October 19, 2021, subject to the satisfaction of customary closing conditions.
  • In addition, PARAGON has granted the underwriters a 30-day option to purchase up to an additional 1,171,875 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Paragon 28, Inc. Announces Pricing of Initial Public Offering

Friday, October 15, 2021 - 3:35am

Paragon 28, Inc. (NYSE: FNA) (PARAGON), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Key Points: 
  • Paragon 28, Inc. (NYSE: FNA) (PARAGON), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.
  • PARAGONs common stock is expected to begin trading on the New York Stock Exchange on October 15, 2021, under the ticker symbol FNA.
  • The offering is expected to close on October 19, 2021, subject to the satisfaction of customary closing conditions.
  • In addition, PARAGON has granted the underwriters a 30-day option to purchase up to an additional 1,171,875 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Esports Betting Industry On PC-Based Games Is On The Upswing

Thursday, October 14, 2021 - 1:55pm

A recent article on iGamingBusiness.com said that: "The issue for sportsbooks offering esports options is that now is not the right time to roll out betting options on mobile gaming.

Key Points: 
  • A recent article on iGamingBusiness.com said that: "The issue for sportsbooks offering esports options is that now is not the right time to roll out betting options on mobile gaming.
  • Most of the money is still in traditional esports played on PCs, and the industry has not adapted tournaments on a massive scale to mobile."
  • The esports betting industry on PC-based games is on the upswing, and sportsbooks need to capitalize on that while keeping an eye on the future.
  • In addition to Esports Technologies, sports betting industry leaders Draft Kings and Penn National as well as top retail and technology companies will be participating in the conference.

Esports Betting Industry On PC-Based Games Is On The Upswing

Thursday, October 14, 2021 - 1:55pm

PALM BEACH,  Fla., Oct. 14, 2021 /PRNewswire/ -- For a long time, the conversation in the gaming world was focused on mobile being the future of the industry. Now, in 2021, the future has officially arrived.  Our society is becoming more dependent on smartphones, with more than 90% of Americans owning a smartphone, and the rest of the developed world is only slightly behind the United States' pace. It is not a surprise that revenue from mobile gaming is rising, but the growth rate is something sportsbooks need to keep an eye on in the future. The more the common gamers pour their money into mobile gaming, the more sportsbooks will need to be ready to pounce. Already more than 40% of smartphone owners are paying at least $50 per month on games, which translates to $600 per year. That isn't a small sum for most people, and a quarter of the users are up to at least $1,000 per year on mobile gaming. Simply put, the future used to be mobile gaming, but it is becoming increasingly apparent that the future is here and the switch from PC gaming to mobile gaming is vital.   A recent article on iGamingBusiness.com said that: "The issue for sportsbooks offering esports options is that now is not the right time to roll out betting options on mobile gaming. While most users are starting to use mobile gaming more than PC or consoles, the competitive gaming world has not made the switch yet. Most of the money is still in traditional esports played on PCs, and the industry has not adapted tournaments on a massive scale to mobile." Active gaming and tech companies in the markets today include:  Esports Technologies (NASDAQ: EBET), Skillz (NYSE: SKLZ), Super League Gaming (NASDAQ: SLGG), Elys Game Technology, Corp. (NASDAQ: ELYS), Golden Nugget Online Gaming, Inc. (NASDAQ: GNOG).

Key Points: 
  • A recent article on iGamingBusiness.com said that: "The issue for sportsbooks offering esports options is that now is not the right time to roll out betting options on mobile gaming.
  • Most of the money is still in traditional esports played on PCs, and the industry has not adapted tournaments on a massive scale to mobile."
  • The esports betting industry on PC-based games is on the upswing, and sportsbooks need to capitalize on that while keeping an eye on the future.
  • In addition to Esports Technologies, sports betting industry leaders Draft Kings and Penn National as well as top retail and technology companies will be participating in the conference.

Esports Technologies CEO Aaron Speach to Participate in Fireside Chat at Needham Consumer Tech/E-Commerce Conference on November 22, 2021

Thursday, October 14, 2021 - 1:29pm

LAS VEGAS, Oct. 14, 2021 /PRNewswire/ -- Esports Technologies, Inc. (Nasdaq: EBET), a leading global provider of advanced esports wagering products and technologies, announced today that CEO Aaron Speach will participate in a fireside chat at Needham & Company's 1st Annual Consumer Tech/E-Commerce Virtual Conference on November 22, 2021.

Key Points: 
  • LAS VEGAS, Oct. 14, 2021 /PRNewswire/ -- Esports Technologies, Inc. (Nasdaq: EBET), a leading global provider of advanced esports wagering products and technologies, announced today that CEO Aaron Speach will participate in a fireside chat at Needham & Company's 1st Annual Consumer Tech/E-Commerce Virtual Conference on November 22, 2021.
  • In addition to Esports Technologies, sports betting industry leaders Draft Kings and Penn National as well as top retail and technology companies will be participating in the conference.
  • "Needham & Company's Consumer Tech/E-Commerce Conference is a unique opportunity to tell investors about major developments at Esports Technologies," said CEO Aaron Speach.
  • Esports Technologies is one of the leading global providers of esports product, platform and marketing solutions.

Lucid Diagnostics Announces Pricing of Initial Public Offering

Thursday, October 14, 2021 - 3:15am

NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share.

Key Points: 
  • NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share.
  • The gross proceeds to Lucid from the offering, before deducting underwriting discounts, commissions and other offering expenses payable by Lucid, are expected to be $70,000,000.
  • In addition, Lucid has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from Lucid at the initial public offering price less underwriting discounts and commissions.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).

Lucid Diagnostics Announces Pricing of Initial Public Offering

Thursday, October 14, 2021 - 2:28am

Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share.

Key Points: 
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share.
  • The gross proceeds to Lucid from the offering, before deducting underwriting discounts, commissions and other offering expenses payable by Lucid, are expected to be $70,000,000.
  • In addition, Lucid has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from Lucid at the initial public offering price less underwriting discounts and commissions.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).